Genelux
Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies for cancer, with lead candidate Olvi-Vec in Phase 3 for platinum-resistant/refractory ovarian cancer.
- Company typePublic
- Founded2008
- HeadquartersWestlake Village, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genelux does
Genelux Corporation is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for the treatment of cancer and inflammatory diseases. Headquartered in Westlake Village, California with R&D and a company-controlled cGMP manufacturing facility in San Diego, the company is publicly listed on NASDAQ under ticker GNLX and was founded in 2008. The company's therapeutic platform centers on a modified vaccinia virus (VACV) backbone and the proprietary CHOICE Discovery Platform, which has generated more than 500 virus constructs armed with over 110 transgenes.
The lead clinical candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified oncolytic vaccinia virus designed to act through three mechanisms: direct tumor cell killing, stimulation of tumor-specific immune response, and conversion of the tumor microenvironment from immunosuppressive ("cold") to immunoreactive ("hot"). Olvi-Vec is in an active Phase 3 registrational OnPrime trial in platinum-resistant/refractory ovarian cancer with topline data expected in the second half of 2026, and in Phase 2 for recurrent non-small cell and small cell lung cancers. Phase 2 ovarian data showed a 54% objective response rate, 11.0-month median PFS, and 15.7-month median OS. Additional programs include the V2ACT combination immunotherapy (joint venture with TVAX Biomedical) for pancreatic and other solid tumors, and the V-VET1 animal health candidate (licensed worldwide to ELIAS Animal Health).
Genelux is pre-revenue with no approved products; commercial economics will depend on regulatory approval of Olvi-Vec and future pipeline assets. Revenue model relies on future direct sales (US) plus licensing royalties through the Newsoara Biopharma partnership for Greater China and the ELIAS Animal Health license for V-VET1. Distribution currently occurs through US clinical trial sites rather than traditional commercial channels, with a small 11-50 person organization that has raised over $109M since 2023 to fund late-stage clinical development.
Genelux firmographics
Firmographics- Name
- Genelux
- Legal name
- Genelux Corporation
- Website
- https://genelux.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies for cancer, with lead candidate Olvi-Vec in Phase 3 for platinum-resistant/refractory ovarian cancer.
- Ownership category
- akta.pro rank
Genelux industry classification
Industry- Product category
- Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Genelux is headquartered
LocationHeadquarters
- HQ city
- Westlake Village
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Genelux business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. No commercial products approved yet. Revenue will be generated upon regulatory approval and commercialization of Olvi-Vec and other pipeline candidates.
- Licensing Royalties: Licensing agreements including exclusive partnership with Newsoara for Olvi-Vec development in China (Greater China Region) and exclusive worldwide licensing agreement for V-VET1 with ELIAS Animal Health. These partnerships generate licensing fees and potential royalty streams.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Genelux product offering
Product offeringCore offering
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for cancer and inflammatory diseases. Its lead clinical candidate Olvi-Vec (olvimulogene nanivacirepvec) is a modified vaccinia virus with a triple mode of action - direct tumor cell killing, tumor-specific immune stimulation, and conversion of immunosuppressive cold tumors to immunoreactive hot tumors - being evaluated in Phase 3 trials for platinum-resistant/refractory ovarian cancer and Phase 2 trials for recurrent lung cancers.
Product overview
Genelux is a late clinical-stage biopharmaceutical company developing a portfolio of oncolytic virus immunotherapies centered on its lead product Olvi-Vec (olvimulogene nanivacirepvec), a modified vaccinia virus that employs a triple mode of action to treat cancer. The company's pipeline includes V2ACT Immunotherapy (a combination therapy approach developed through a joint venture) and V-VET1 (an animal health product for canine cancer). The CHOICE™ Discovery Platform serves as the proprietary engine for generating new product candidates, having produced over 500 different vaccinia virus constructs.
Differentiator
Problem solved
Functional benefit
Brands
- CHOICE: Proprietary discovery platform serving as the foundation of Genelux's oncolytic immunotherapy product development program. CHOICE has produced more than 500 different versions of the vaccinia virus armed with over 110 transgenes.
- V2ACT
- Olvi-Vec
Products and services
- Olvi-Vec (olvimulogene nanivacirepvec) A modified vaccinia virus (oncolytic immunotherapy) that directly kills cancer cells, stimulates a tumor-specific immune response, and converts the tumor microenvironment from immunosuppressive (cold) to immunoreactive (hot). Being evaluated as Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer and recurrent lung cancers.
- V2ACT Immunotherapy Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy - a proprietary indication-agnostic personalized anti-cancer therapy combining neoantigen-specific effector T cell immunotherapy with oncolytic immunotherapy (Olvi-Vec). Being developed by V2ACT Therapeutics LLC joint venture for pancreatic and other solid tumor cancers.
- V-VET1 A genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus (naturally attenuated isolate) for treatment of canine cancers. Being developed by ELIAS Animal Health under an exclusive worldwide licensing agreement.
Quantifiable outcome
- 54% objective response rate (ORR), 11.0 months median progression-free survival (PFS), 15.7 months median overall survival (OS) in Phase 2 PRROC trial
- +2 more outcomes
Companies that use Genelux
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles3 records
Genelux technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Genelux partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered secondary and core.
- ELIAS Animal HealthsecondaryOn November 21, 2021, Genelux entered into an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health. ELIAS is a biotechnology company working to advance its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis).
- Newsoara Biopharma Co., Ltd.coreOn September 28, 2021, Genelux entered into an exclusive rights agreement with Newsoara Biopharma Co., Ltd for Olvi-Vec and the Genelux oncolytic virus library in the Greater China Region. Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world.
- V2ACT Therapeutics, LLCcoreIn January 2019, V2ACT Therapeutics, LLC was formed as a joint venture between Genelux Corporation and TVAX Biomedical, Inc. to develop and test V2ACT Immunotherapy, a novel immunotherapy modality combining oncolytic virotherapy and adoptive cell therapy to safely achieve superior efficacies for the treatment of pancreatic and other solid tumor cancers.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Genelux competitors and assessment
Company assessmentBroad incumbents
- Amgen: Amgen is the broad incumbent with the only FDA-approved oncolytic virus (T-VEC/Imlygic for melanoma), making it the most established player in the oncolytic immunotherapy space where Genelux's Olvi-Vec competes.
- Iovance Biotherapeutics: Iovance is a leading cell therapy company with approved tumor-infiltrating lymphocyte therapies for solid tumors, sharing Genelux's focus on immuno-oncology and (via the V2ACT JV) adoptive cell therapy combinations.
Direct peers
- Replimune: Replimune is a direct peer developing a portfolio of oncolytic immunotherapies (RP1, RP2, RP3) based on engineered herpes simplex virus for multiple solid tumor indications, directly competing with Genelux's Olvi-Vec program.
- CG Oncology: CG Oncology is a direct peer developing CG0070, an oncolytic virus (GM-CSF expressing adenovirus) for bladder cancer, sharing Genelux's oncolytic virus immunotherapy approach for solid tumors.
- Turnstone Biologics: Turnstone Biologics (now Turnstone Biotherapeutics) develops oncolytic virus immunotherapies combining viral therapy with immune stimulation, sharing Genelux's mechanism of converting cold tumors to hot tumors.
- Candel Therapeutics: Candel Therapeutics develops oncolytic immunotherapies including CAN-2409 for prostate cancer, sharing Genelux's virotherapy approach to converting tumor microenvironments and generating anti-tumor immune responses.
- TVAX Biomedical: TVAX Biomedical is Genelux's joint venture partner in V2ACT Therapeutics, developing personalized cancer immunotherapies combining oncolytic virotherapy with adoptive cell therapy, making it directly comparable in the virotherapy plus cell therapy combination space.
Emerging players
- Oncorus: Oncorus develops intratumoral oncolytic virus immunotherapies using synthetic double-stranded RNA approaches, representing an emerging player in the oncolytic immunotherapy space adjacent to Genelux's systemic delivery approach.
- Chimeric Therapeutics: Chimeric Therapeutics develops cell therapy and oncolytic virus approaches for cancer, including former CMO Dr. Jason Litten who joined Genelux — making it thematically comparable in virotherapy and cell therapy combinations.
- Artiva Biotherapeutics: Artiva Biotherapeutics develops off-the-shelf NK cell therapies for cancer, sharing Genelux's interest in scalable immuno-oncology approaches; also a former employer of Genelux's new CMO.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Genelux social profiles
Digital presenceGenelux financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genelux leadership team
Management profileNumber of profiles
Profiles12 records
Genelux subsidiaries and ownership
Company hierarchySubsidiaries3 records
Genelux funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genelux M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genelux
What does Genelux do?
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for cancer and inflammatory diseases. Its lead clinical candidate Olvi-Vec (olvimulogene nanivacirepvec) is a modified vaccinia virus with a triple mode of action - direct tumor cell killing, tumor-specific immune stimulation, and conversion of immunosuppressive cold tumors to immunoreactive hot tumors - being evaluated in Phase 3 trials for platinum-resistant/refractory ovarian cancer and Phase 2 trials for recurrent lung cancers.
Is Genelux a public or private company?
Genelux is a public company. It is classified as public and is currently operating.
When was Genelux founded?
Genelux was founded in 2008. It employs 11 to 50 people.
Where is Genelux based?
Genelux is headquartered in Westlake Village, United States, in the North America region.
How does Genelux make money?
Two revenue lines are on record. Pharmaceutical Development is the primary driver. The others are licensing Royalties.
Who are Genelux's main competitors?
Broad incumbents on record are Amgen and Iovance Biotherapeutics. Direct peers are Replimune, CG Oncology, Turnstone Biologics, Candel Therapeutics and TVAX Biomedical. Emerging players are Oncorus, Chimeric Therapeutics and Artiva Biotherapeutics.
Does Genelux have an API?
No public API is recorded for Genelux.
What industry is Genelux in?
Genelux's product category is Oncolytic Virus Immunotherapy (Clinical-Stage Biopharmaceuticals). Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.